SpringWorks Launches With $103m, Four Pfizer Drugs And A Focus On Underserved Patients
No disease is too small or too large for SpringWorks, which spun out Pfizer with four mid-/late-stage compounds to develop drugs in indications where patients have no good treatment options.
You may also be interested in...
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Response rates for multiple myeloma patients treated with BCMA-targeting bispecific antibodies are lower than for CAR-T therapies, but adverse event rates are lower for the off-the-shelf treatments.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.